Department of Brain Health News
The UNLV Department of Brain Health will advance research, education, and practice to benefit brain health and the care and treatment of people with brain disorders across the life span. Our faculty specialize in several areas that range from basic and clinical research in neurodegenerative disease, neuropsychology, and occupational therapy.
Current Brain Health News
A collection of news stories from 2019 highlighting UNLV's impact in Southern Nevada and beyond.
A collection of stories highlighting UNLV faculty and students who made the news in 2019.
UNLV’s new Department of Brain Health leads interdisciplinary effort to answer tough questions about traumatic brain injury.
A collection of local, national, and international news stories highlighting the people and programs of UNLV.
A collection of local, national, and international news stories highlighting the people and programs of UNLV.
Lou Ruvo Center for Brain Health neurologist Dr. Jeffrey Cummings joins UNLV to help launch new program that will be crucial for an aging state population.
Brain Health In The News
Jefferson Kinney, the founding chairman of the UNLV Cellular and Molecular Brain Research Laboratory, said the lab was created, in part, to complement the brain health center’s work.
As new treatments are developed for traumatic brain injury and Alzheimer’s disease, a significant amount of credit could go to UNLV’s new Department of Brain Health.
Biogen Inc. stunned Alzheimer’s researchers in March when it said its highly awaited Alzheimer’s treatment aducanumab was unlikely to work. Seven months later, the company reversed course and said the drug did work after all -- at least in one of two large trials.
Nearly fifty-thousand Nevadans are currently living with Alzheimer's, and that number is only expected to skyrocket over the next decade. On this Nevada Week, we'll explore how close local researchers are to a cure. Plus, what role do citizen scientists and caregivers play toward fighting this neurodegenerative disease?
China has approved its first homegrown Alzheimer’s treatment — a novel drug based on algae, and the first breakthrough since 2003 in a field that has frustrated scientists and drug companies for decades.
Shanghai Green Valley Pharmaceuticals (Green Valley) today announced that China's National Medical Products Administration (NMPA) has approved Oligomannate (GV-971) as new drug for the treatment of "mild to moderate Alzheimer's disease (AD) and improving cognitive function."
